InCarda Therapeutics has been issued patents in the United States, Australia and Canada covering the company’s inhaled flecainide for the treatment of paroxysmal atrial fibrillation (PAF), the company said. Those patents include US patent No. 8,974,828, issued in March 2015 and titled, “Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary administration.”
The company, which announced in April 2015 that it had raised $5 million for development of the product, says that it is currently conducting a toxicology study and plans to begin a Phase 1 trial in early 2016.
InCarda President and CEO Grace E. Colón commented, “The issuance of this important patent strengthens the IP position around our product candidates, protecting our novel and exciting product platform. We continue to add to our patent estate with additional proprietary concepts we believe will transform cardiovascular care. It appears that delivery of effective cardiovascular medications through the pulmonary system may provide much quicker relief of symptoms and significantly reduce the burden on the healthcare system related to these cardiovascular episodes.”
COO and Co-Founder Narsi Rangachari added, “Flecainide is a first line drug of choice to treat paroxysmal atrial fibrillation (PAF) in patients with minimal structural heart disease. At InCarda we are developing a fast acting inhaled version of this drug for quick relief from the disabling symptoms often experienced with an acute episode.”
Read the InCarda press release.
